Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Impairment of book values of goodwill in Eniro AB and report for the fourth quarter and the full year 2018

At its meeting today, the Board of Directors of Eniro AB has resolved to conduct impairment of the book values of goodwill totaling approximately SEK -565 million. The non-cash flow impairment is charged to earnings in the fourth quarter of 2018. Today, Eniro also publishes its report for the fourth quarter of 2018 and the full year 2018. Eniro's operating income for the fourth quarter amounts to SEK -565 million, which includes impairment of the book values of goodwill of SEK -565 million. The impairment has no cash flow effect. Testing of the value of all of the Group’s intangible

Tethys Oil 2018 reserves development – 2P reserve replacement ratio 177 percent

Tethys Oil’s net working interest Reserves in Blocks 3&4 Oman as per 31 December 2018 amount to 25,357 thousand barrels of oil (“mbo”) of proven and probable Reserves (2P). The 2P reserve replacement ratio amounts to 177 percent. In addition, Tethys Oil's net working interest resources oil base in Oman amounts to 12,533 mbo of 2C Contingent Resources. The Company’s 2018 and 2017 year-end Reserves reports were audited by ERC Equipoise Limited (“ERCE”) as independent qualified Reserves evaluator.Development of Reserves, Blocks 3&4 (Audited)mbo 1P 2P

Tethys Oil announces 2019 investments and production guidance

· 2019 investments: MUSD 50-55 · 2019 production: annual average of 12,000-13,000 bopdInvestments Under current market conditions and production assumptions, Tethys Oil expects its 2019 investments for the company’s existing operations on Blocks 3&4 and Block 49 in Oman to amount to MUSD 50-55. Focus of the work program in Blocks 3&4 is continued development and appraisal drilling, upgrading of production facilities and other infrastructure, new seismic acquisition and drilling of exploration wells. Focus on Block 49 is to continue the exploration programme. The new seismic data

Ericsson and Intel jointly develop next-generation software defined infrastructure for the 5G era

· Ericsson and Intel are teaming up to develop the next-generation hardware management platform · The joint development will provide a new level of cloudlike agility, transparency and efficiency required for Network Functions Virtualization (NFV), distributed cloud, and 5G · The companies will align development efforts of Ericsson SDI Manager software and Intel® Rack Scale Design (Intel® RSD) and extend these solutions with advanced management capabilitiesEricsson (NASDAQ: ERIC) and Intel Corporation have begun a multi-year collaboration to align ongoing development efforts in

Starbreeze sells back ”System Shock 3” publishing rights to OtherSide Entertainment

STOCKHOLM, SWEDEN (February 11, 2019) – Starbreeze and OtherSide Entertainment have mutually agreed to sell back the publishing rights to OtherSide Entertainment for “System Shock 3”. Starbreeze expects to be fully reimbursed for costs the company has had in connection with development of the game.  Starbreeze acquired the publishing rights for “System Shock 3” in 2017 and has since then partly financed the development of the game. The title owner OtherSide Entertainment and Starbreeze have now reached an agreement whereby Starbreeze returns the publishing rights for the game to

VALMET Oyj: ACQUISITION OF OWN SHARES 11.02.2019

Valmet Oyj NOTIFICATION 11.02.2019 at 18:30 VALMET Oyj: ACQUISITION OF OWN SHARES 11.02.2019 Date 11.02.2019Exchange transaction OstoShare class VALMTAmount 23,000Average price/share 21.4296 EURHighest price/share 21.7400 EURLowest price/share 20.7600 EURTotal price 492,880.80 EUR The shares held by Valmet Oyj on 11.02.2019: VALMT 270,706 On behalf of Valmet Oyj Skandinaviska Enskilda Banken AB (Publ) Antti Salakka Janne Tiihonen For more information, please contact:Tuomas

Clarification – UAE statements on launching Brighter’s diabetes service Actiste.

During Arab Health 2019, January 28-31, MOHAP (UAE Ministry of Health and Prevention) made an official statement on Brighter’s diabetes service Actiste  in a press release. In the press release, MOHAP states that the Ministry launches Actiste in the United Arab Emirates along with Brighter as part of the Ministry’s keenness to offer UAE residents a modern and effective healthcare system with the highest rates of quality. The announcement in full can be reached via the following link:http://www.mohap.gov.ae/en/MediaCenter/News/Pages/2030.aspx Based on these

Moberg Pharma and Bayer sign exclusive license agreement for MOB-015 in Europe

STOCKHOLM, February 11th, 2019, Moberg Pharma AB (OMX: MOB) has signed an exclusive license agreement with Bayer for commercialization of MOB-015 in Europe. Under the agreement, Moberg Pharma is eligible to receive up to EUR 50 million contingent on development and commercial success, as well as supply fees including royalties.Moberg Pharma has entered into a license agreement granting the Consumer Health division of Bayer exclusive European rights to MOB-015, a new topical treatment of onychomycosis based on Moberg’s patented proprietary formulation of terbinafine. Bayer will be marketing,

FISKARS CORPORATION: ACQUISITION OF OWN SHARES 11.02.2019

Fiskars Corporation  NOTIFICATION 11.02.2019 at 18:30 EEST FISKARS CORPORATION: ACQUISITION OF OWN SHARES 11.02.2019 Date 11.02.2019Exchange transaction BuyShare class FSKRSAmount       1 500Average price/share 19.5433 EUR  Highest price/share 19.7000 EUR Lowest price/share 19.4600 EUR Total price 29,314.95  EUR  The shares held by Fiskars Corporation on 11.02.2019: FSKRS 341,560  On behalf of Fiskars Corporation Skandinaviska Enskilda Banken AB (Publ) Antti Salakka   Janne Tiihonen

Change in Citycon’s Corporate Management Committee

CITYCON OYJ   Stock Exchange Release   11 February 2019 at 18:15 hrsTom Lisiecki, Citycon’s Chief Development Officer and member of the Corporate Management Committee has decided to leave the company to pursue new opportunities outside the company. At the same time he will step down from Citycon´s Corporate Management Committee. The company thanks Tom Lisiecki for his contribution. Espoo, 11 February 2019 For further information, please contact: Mikko PohjalaIR and Communications DirectorTel. +358 40 838 0709mikko.pohjala@citycon.com   Citycon is a leading owner,

STOREBRAND ASA: Storebrand strengthens private equity position through acquisition of Cubera

Storebrand Asset Management has entered into an agreement to acquire Cubera Private Equity [Cubera]. Cubera is a Nordic firm offering investors exposure to Nordic private equity primarily through the secondary market. The firm is a leading player within Nordic private equity and has around NOK 9 billion under management, mainly from international investors. - The transaction strengthens our offering to institutional asset management clients. Storebrand is today the only provider in Norway that includes private equity in its defined contribution portfolios, says Group CEO Odd Arild

BioArctic: U.S. Food and Drug Administration Approves Investigational New Drug Applicationfor ABBV-0805

· ABBV-0805 is being evaluated as a potential disease modifying treatment for Parkinson’s Disease Stockholm, Sweden, February 11, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that AbbVie has received approval from the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for ABBV-0805. This is a requirement to start clinical trials in the U.S. ABBV-0805, previously named BAN0805, is the most advanced within the portfolio of alpha-synuclein targeting antibodies in-licensed by AbbVie from BioArctic in December 2018. The

Ossur Hf : Transactions in relation to share buyback program

Announcement no. 09/2019 11 February 2019  Transactions in relation to share buyback program On 9 October 2018, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2018. The purpose of the share buyback program is to reduce the Company's share capital and adjust the capital structure by distributing capital to shareholders in line with the Company's Capital Structure and Dividend Policy. The program will end no later than 30 June 2019. The Company may purchase up to 5,000,000 shares under the program, corresponding to 1.2% of the current share capital.

CXENSE ASA – Approval and publication of the prospectus for the rights issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, HONG KONG OR SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. As previously announced, Cxense ASA (the "Company") will carry out a fully underwritten rights issue (the "Rights Issue") of 12,857,142 new shares in the Company (the "Offer Shares") at a subscription price of NOK 7, raising

Biohit Oyj: Managers' Transactions

BIOHIT Oyj           MANAGERS’ TRANSACTIONS                               11 FEBRUARY 2019  05.45 P.M.Biohit Oyj: Managers' Transactions  Biohit Plc - Managers' transactions - Söderström____________________________________________ Person subject to the notification requirementName: Söderström, DanielaPosition: Other senior managerIssuer: Biohit PlcLEI: 74370089ATTSNBXJVT29 Notification type: INITIAL NOTIFICATIONReference number: 74370089ATTSNBXJVT29_20190211164318_4____________________________________________ Transaction date: 2019-02-06Instrument type: SHAREISIN: FI0009005482Nature of

New European sites in Immunovia’s PanFAM-1, the largest ever prospective multicenter clinical study for early detection of pancreatic cancer

New centers in Sweden and Spain broaden sample ethnic and racial diversity in drive to validate IMMrayTM PanCan-d, the first blood-based test for early detection of pancreatic cancer.LUND, SWEDEN ― Immunovia AB today announced that two additional sites, Umeå University Hospital in Sweden and Catalan Institute of Oncology (ICO Hospitalet) – Bellvitge Biomedical Research Institute (IDIBELL) in Barcelona, are now part of PanFAM-1, the largest ever prospective study looking at early diagnosis in high-risk individuals with Familial Pancreatic Cancer (FPC). Designed to validate Immunovia ́s

Nomination Committee’s proposal for Board of Directors and Chairman of Gränges AB (publ)

The Nomination Committee of Gränges AB (publ) proposes that the Board members Anders G. Carlberg, Carina Andersson, Mats Backman, Peter Carlsson, Katarina Lindström, Hans Porat and Ragnhild Wiborg will be re-elected at the Annual General Meeting 2019. Anders G. Carlberg is proposed to be re-elected as Chairman of the Board. Gränges’ Nomination Committee before the Annual General Meeting 2019 consists of representatives of the company's three largest shareholders and Gränges’ Chairman of the Board. Prior to the Annual General Meeting 2019, Gränges’ Nomination Committee has the following

ADDvise enters into an agreement to acquire Sonar Oy

ADDvise Group AB (publ) (”ADDvise”) has today entered into an agreement with the shareholders of the Finnish company Sonar Oy (“Sonar”) regarding the acquisition of all shares in Sonar. The closing is expected to take place on March 1st, 2019 (the “Acquisition”). The signing of the Letter of Intent regarding the Acquisition was made public in a press release on December 12th, 2018. · The purchase price amounts to MEUR 3.2 (corresponding to MSEK 33.6) and is based on a cash and debt free basis and will be paid in cash. · An earn-out of a maximum of MEUR 1.1 (corresponding to MSEK 11.

Scandi Standard – Fourth quarter presentation

Scandi Standard will publish its report for the fourth quarter 2018 on Wednesday, 20 February 2019 at 07.30 CET. Conference call at 08.3o CETThe Company will host a conference call for the financial community at 08.30 CET the same day.The conference call will be hosted by Leif Bergvall Hansen, CEO and Anders Hägg, CFO. Dial in numbers: Sweden: 010 884 80 16UK: 020 3936 2999USA: 1 845 709 8568All other locations: +44 20 3936 2999 Participant Access Code: 31 46 39 The presentation used in the conference call will be published at http://www.scandistandard.com prior to

Minesto raises SEK 44.4 million from warrants program

Marine energy developer Minesto has concluded its warrants program of series TO 2. In total, 98 percent of outstanding warrants were exercised, which means that Minesto will add approximately SEK 44.4 million in proceeds before issue costs to the commercialisation activities of the company’s unique subsea kite technology.Commenting on the outcome of the warrants program Minesto’s CEO Dr Martin Edlund said: “We are pleased that so many have chosen to exercise their warrants and subscribe for new shares in Minesto. We will use this capital injection together with our other sources of funding

#19-333 Listing of Knock out warrants issued by BNP Paribas Issuance B.V.

As from February 12, 2019, 3 Knock out warrants issued by BNP Paribas Issuance B.V. will be listed on ETP Sweden and will be included on the list for Knock-Outs. The instruments will be registered at Euroclear Sweden AB.Issuer: BNP Paribas Issuance B.V. Type of security: Knock out warrants, open ended Execution: Automatic cash settlement Term: As from February 12, 2019 and forward or until time for knock out event Market Maker: BNP Paribas Arbitrage SNC Underlying: DAX 30 Index OMXS30 index Current values of strike and barrier can be found at: [ NGM Market Data

#19-332 Listing of Turbo warrants issued by BNP Paribas Issuance B.V.

As from February 12, 2019, 6 Turbo warrants issued by BNP Paribas Issuance B.V. will be listed on ETP Sweden and will be included on the list for Knock-Outs. The instruments will be registered at Euroclear Sweden AB.Issuer: BNP Paribas Issuance B.V. Type of security: Call and put Turbo warrants of European type Execution: Automatic cash settlement Term: As from February 12, 2019 to expiry date Market Maker: BNP Paribas Arbitrage SNC Underlying: DAX 30 Index OMXS30 index For more details see attached file. For further information concerning this NGM notice please

#19-331 Listing of Mini futures issued by BNP Paribas Issuance B.V.

As from February 12, 2019, 6 Mini futures issued by BNP Paribas Issuance B.V. will be listed on ETP Sweden and will be included on the list for Knock-Outs. The instruments will be registered at Euroclear Sweden AB.Issuer: BNP Paribas Issuance B.V. Type of security: Mini futures, open ended Execution: Automatic cash settlement Term: As from February 12, 2019 and forward or until time for knock out event Market Maker: BNP Paribas Arbitrage SNC Underlying: EUR/SEK Exchange Rate EUR/USD Exchange Rate USD/SEK Exchange Rate ICE Brent Crude Oil Futures Current values

There are no items matching the current filter
There are no more items matching the current filter
Back to top